Compare Nuscale Power Corporation (SMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Sanofi SA — how do they compare? Nuscale Power Corporation trades at $7.18 (market cap $3.00B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 31.7× Nuscale Power Corporation's market cap, and Sanofi SA pays a 6.01% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and Sanofi SA for 94 Days on average.
| SMR | SNY | |
|---|---|---|
Market Cap | $3.00B | $95.18B |
Volume | 43,143,109 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $53.43 | $52.34 |
52-Week Low | $7.32 | $39.51 |
Typical Hold Time | 29 Days | 94 Days |
Enterprise Value | $1.93B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $7.20, down 6.13% with bearish technical signals. The company shows concerning fundamentals with negative net income margins (-3,888.7% in 2026) despite analyst consensus of $11.25 price target. Recent news highlights ongoing investor investigations and competitive pressures in the nuclear energy sector.
While analysts maintain 50% buy ratings, significant operational losses and cash burn create substantial risk. The stock faces headwinds from execution challenges and dilution concerns, though long-term nuclear energy adoption trends provide potential upside for patient investors.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
